Search clinical trials for: BI 201335

Total 1295 results

University of Sao Paulo General Hospital
Abbott

Not yet recruiting

Cardiac Autonomic Denervation for Cardio-inhibitory Syncope (CardioSync)

Syncope, Vasovagal | Bradycardia; Syncope

Brazil
Boehringer Ingelheim

Active, not recruiting

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Liposarcoma, Dedifferentiated

United States, Spain, Canada, Taiwan, Belgium, Australia, China, Italy, Germany, Japan, Hong Kong, Finland, United Kingdom, Denmark, France, Sweden, Netherlands, Portugal, Czechia, Greece, Norway
Boehringer Ingelheim

Completed

BI 10773 Administered as Oral Solution to Healthy Male Volunteers

Healthy
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Avian Influenza

United States
Mylan Inc.
Mylan GmbH

Completed

Mylan Insulin Glargine Study

Diabetes Mellitus, Type 1

United States
Massachusetts General Hospital
Boston University

Completed

Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas

Type 1 Diabetes

United States
Boehringer Ingelheim

Completed

Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Diabetes Mellitus, Type 2

United States, Canada, Greece, India, Philippines, Thailand, Ukraine
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other

Healthy

Germany
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects

Healthy
University of Oslo

Not yet recruiting

Early Intervention Coping Kids (TIM) Follow up Study (FOPPT4)

Depression | Anxiety Disorders
Boehringer Ingelheim

Completed

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

Healthy
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Boston University Charles River Campus
Massachusetts General Hospital; National Institute of Diabetes and Digestive... and other collaborators

Completed

Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas (CL2)

Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Asahi Kasei Pharma Corporation

Recruiting

Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
SIGA Technologies
United States Department of Defense

Completed

Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days

Smallpox

United States
Gradalis, Inc.

Completed

A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

Ovarian Cancer

United States
Sangath

Completed

Alcohol Use Disorders- Mobile Based Brief Intervention Treatment (AMBIT): A Pilot RCT (AMBIT)

Hazardous Drinking

India
Boehringer Ingelheim

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

Healthy
Cytokinetics

Completed

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, United Kingdom, Germany, Canada, Netherlands, France, Ireland, Spain
Assistance Publique - Hôpitaux de Paris

Recruiting

Follow-up in Pediatric Intensive Care Unit (APRELAREA)

Intensive Care Psychosis

France
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, United States, Japan, France, Israel, Bulgaria, Italy, Switzerland, Netherlands, Portugal
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

Influenza

United States
Cytokinetics

Completed

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Cephalon

Completed

Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.

Anxiety Disorders

United States, Canada
Boehringer Ingelheim

Completed

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Healthy
Hospices Civils de Lyon

Unknown

Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children (COVAGREF)

Transplantation

France
Boehringer Ingelheim

Completed

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Alzheimer Disease

United States, Canada, United Kingdom, Germany, Portugal, France, Belgium, Netherlands, Austria, Poland, Italy
Boehringer Ingelheim

Completed

12 / 48 wk Pivotal PFT vs PBO in COPD II

Pulmonary Disease, Chronic Obstructive

United States, China, Germany, Taiwan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
AbbVie
Boehringer Ingelheim

Completed

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Advanced Malignancies

United Kingdom, Denmark, Hungary, Russian Federation
Peking Union Medical College Hospital

Completed

Analyse of Diagnosis Value of Keloid on 68Ga- FAPI-04 PET-CT

Keloid

China
Boehringer Ingelheim

Completed

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Diabetic Nephropathies

Spain, Germany, United Kingdom, France, Greece, Portugal, Sweden, Russian Federation, Denmark, Slovakia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)

Healthy

Netherlands
Boehringer Ingelheim

Completed

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers

Healthy
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Influenza A Virus, H7N9 Subtype

United States
Northwestern University
Lynn Sage Foundation

Completed

Cabergoline in Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Gradalis, Inc.

Active, not recruiting

A Trial of Vigil for Participants With Ovarian Cancer (VITAL)

Ovarian Neoplasms | Ovarian Cancer

United States
SIMmersion, LLC
Towson University

Unknown

Simulated Conversation Training for Mental Healthcare Providers to Improve Care for Transgender and Gender Nonconforming Individuals

Gender Affirming Communication Skills

United States
University of Melbourne

Completed

Influenza Vaccine in HIV Study

Influenza, Human
InxMed (Shanghai) Co., Ltd.

Not yet recruiting

IN10018 Combination Therapy in Previously-treated Solid Tumors

Solid Tumor

3

Subscribe